Nuvation Bio Inc. (NYSE:NUVB – Get Free Report) CFO Philippe Sauvage sold 47,668 shares of Nuvation Bio stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $6.01, for a total transaction of $286,484.68. Following the completion of the transaction, the chief financial officer owned 12,673 shares of the company’s stock, valued at $76,164.73. This represents a 79.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Nuvation Bio Trading Down 10.0%
NYSE NUVB opened at $5.82 on Friday. Nuvation Bio Inc. has a 52 week low of $1.81 and a 52 week high of $9.75. The firm has a 50 day moving average of $4.93 and a two-hundred day moving average of $5.72. The company has a quick ratio of 7.24, a current ratio of 7.44 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $2.02 billion, a PE ratio of -13.52 and a beta of 1.52.
Nuvation Bio (NYSE:NUVB – Get Free Report) last announced its quarterly earnings data on Monday, May 4th. The company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.04. The business had revenue of $83.23 million for the quarter, compared to analyst estimates of $66.22 million. Nuvation Bio had a negative net margin of 102.06% and a negative return on equity of 44.10%. As a group, research analysts expect that Nuvation Bio Inc. will post -0.39 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
A number of research analysts have recently commented on NUVB shares. Royal Bank Of Canada reiterated an “outperform” rating and issued a $20.00 price objective on shares of Nuvation Bio in a report on Tuesday, May 5th. UBS Group decreased their target price on Nuvation Bio from $10.00 to $7.00 and set a “neutral” rating for the company in a research note on Tuesday, March 3rd. Zacks Research downgraded Nuvation Bio from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 26th. Citigroup reiterated a “market outperform” rating on shares of Nuvation Bio in a research note on Wednesday, June 10th. Finally, Wedbush reissued an “outperform” rating and set a $11.00 price objective on shares of Nuvation Bio in a report on Tuesday, May 5th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.50.
Get Our Latest Stock Analysis on Nuvation Bio
Nuvation Bio Company Profile
Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.
The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.
Featured Stories
- Five stocks we like better than Nuvation Bio
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for Nuvation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio and related companies with MarketBeat.com's FREE daily email newsletter.
